Certara's core business model is now majority software, with a strong recurring revenue base and high margins in that segment. The company's regulatory-grade software and integration into drug development workflows create defensibility, but services remain execution-sensitive. AI integration is a r…
Certara (CERT) Q2 2026: Software Mix Hits 53% as AI and Pipeline Expansion Drive Strategic Reset
Certara’s Q2 marks a pivotal shift toward a software-centric, AI-enabled model, with pipeline growth and operational resets positioning the company for midterm acceleration. Despite muted top-line growth, Certara’s divestiture, cost actions, and AI integration signal a business in active transformation, with execution now the primary lever for future upside. Management’s unchanged guidance and new leadership hires set the stage for a more focused, data-driven commercial approach in the second half and beyond.
Summary
- Software Share Surges: Certara’s business mix now tilts decisively toward software, reflecting strategic portfolio rebalancing.
- AI-Driven Productivity: Embedded AI accelerates product development and operational efficiency, setting new benchmarks for internal execution.
- Pipeline Expansion: A 27% YoY pipeline increase underpins management’s confidence in second-half reacceleration.
Business Overview
Certara is a global provider of biosimulation software and scientific services for biopharma and life sciences clients, enabling model-informed drug development (MIDD, using computational models to optimize drug design and regulatory submissions). The company generates revenue through two main segments: software (53% of revenue), including platforms like Phoenix and Simcyp for simulation and modeling, and scientific services (47%), which deliver consulting and regulatory support. Certara’s solutions are deeply embedded in client workflows and regulatory processes, serving over 2,600 customers across 70 countries.
Performance Analysis
Certara’s Q2 2026 results reflect a business in strategic transition. Overall revenue growth was a modest 1% YoY, with software revenue up 4% and services revenue down 3%. Software’s share of the business expanded to 53%, up from 40% two years ago, driven by strong performance in Phoenix, Simcyp, and Pinnacle 21. Services lagged, impacted by the divestiture of the regulatory and medical writing business and a deliberate reset of the go-to-market approach. Bookings growth was similarly muted, with total bookings up 1% and software bookings up 9% YoY.
Cost structure remains a focal point as Certara works to offset stranded costs from the divestiture and streamline operations. Adjusted EBITDA margin landed at 28.1%, with management pointing to $13 million in anticipated run rate savings from a recent reduction in force and other overhead actions. The company finished the quarter with $184 million in cash and completed a $100 million share repurchase program, authorizing an additional $50 million for buybacks. Guidance for 2026 revenue remains unchanged at 0% to 4% growth, signaling management’s confidence in pipeline conversion and software momentum for the back half.
- Software Mix Shift: Software now dominates Certara’s revenue, reflecting a multi-year pivot toward recurring, scalable business lines.
- Services Under Pressure: Services bookings and revenue remain soft, with improvement tied to execution on a newly retooled commercial model.
- Cost Reduction in Focus: Operational savings and divestiture actions are key to protecting margins and funding innovation.
While top-line growth is subdued, leading indicators such as a 27% YoY pipeline increase and robust ARR accumulation in software suggest the building blocks for reacceleration are in place—provided execution keeps pace.
Executive Commentary
"We are transforming Sertara into a company we believe is capable of delivering sustainable double-digit growth. We still have work to do, but we are on the right path. We are executing against our plan. Our foundation is strengthening in the macro market condition."
John Resnick, Chief Executive Officer
"The reduction in force we completed at the start of the third quarter offsets a meaningful portion of that impact, and we expect margins to improve through the second half as those savings are realized."
Saeed Muhammad, Interim Chief Financial Officer
Strategic Positioning
1. Software-Centric Realignment
Certara’s divestiture of its regulatory and medical writing business and the resulting 53% software mix mark a decisive shift toward recurring, high-margin revenue streams. This realignment is expected to improve predictability and position the company to capitalize on regulatory trends favoring model-informed approaches.
2. AI Integration and Operational Leverage
AI is now deeply embedded across Certara’s product and internal workflows, with 85% of new code AI-assisted and a 65% YoY increase in development velocity per engineer. AI agents are automating legal, IT, and sales processes, slashing cycle times and boosting productivity. This not only improves margins but also accelerates innovation in customer-facing products.
3. Commercial Model Overhaul
The appointment of a new Chief Commercial Officer and a reorganization around two business units (MID3 and ACE) signals a more targeted, data-driven approach to sales and marketing. The focus on specialist, science-led engagement—particularly in services—is designed to reverse recent softness and unlock pipeline conversion.
4. Global Expansion and Ecosystem Positioning
Certara is leveraging regulatory harmonization (such as ICH M15) and new wins in China, Japan, and the Middle East to extend its international footprint. The company’s partnerships, including with NVIDIA, reflect a strategy to integrate frontier AI models and expand platform capabilities for discovery and clinical development.
5. Portfolio Reprioritization and Cost Discipline
Product roadmaps have been reprioritized to accelerate AI features and customer use cases, while a $13 million run rate cost reduction program is freeing up capital for innovation and margin protection. The company is actively addressing stranded costs from the divestiture and streamlining overhead.
Key Considerations
Certara’s Q2 underscores a business in the midst of a strategic reset, with management actively reshaping commercial, operational, and technological levers to build a platform for sustainable growth. The following considerations are critical for investors:
Key Considerations:
- Pipeline Conversion Timing: The 27% YoY pipeline increase is promising, but conversion into bookings and revenue is the key swing factor for H2.
- AI-Driven Differentiation: Certara’s proprietary, regulated AI workflows create barriers to entry, but market adoption and customer trust will determine commercial impact.
- Services Execution Risk: Success of the new specialist-driven commercial model is essential to stem services decline and unlock growth.
- Margin Recovery Trajectory: Realizing the full benefit of cost reductions is necessary to achieve targeted EBITDA margins post-divestiture.
- Capital Allocation Discipline: The new $50 million buyback authorization signals confidence, but future M&A or investment priorities remain a watchpoint.
Risks
Certara faces execution risk as it implements a new commercial strategy and seeks to convert pipeline into revenue, particularly in services. Regulatory changes and evolving customer adoption of model-informed approaches could introduce variability in demand. Stranded costs from the divestiture, competitive pressure from peers and new AI entrants, and the pace of international expansion all present additional uncertainties. Management’s unchanged guidance despite muted first-half growth puts pressure on delivery in the back half.
Forward Outlook
For Q3 and Q4 2026, Certara guided to:
- Continued software outperformance versus services
- Margin improvement as cost savings are realized
For full-year 2026, management reaffirmed guidance:
- Revenue growth of 0% to 4% ($367 to $382 million)
- Adjusted EBITDA margin of 29% to 31%
- Adjusted diluted EPS of $0.31 to $0.36
Management highlighted strong ARR and pipeline indicators in software, a deliberate focus on pipeline conversion in services, and ongoing investments in AI as drivers for second-half performance.
- Realization of cost savings from the reduction in force
- Execution of the new go-to-market model under the new CCO
Takeaways
Certara’s Q2 demonstrates a business in active transformation, with software now the majority and AI integration accelerating operational leverage. The path to double-digit growth hinges on execution against a growing pipeline and successful adoption of a specialist-led commercial model.
- Execution Is the Key Lever: With foundational resets in place, the company’s ability to convert pipeline and drive services recovery will determine near-term upside.
- AI and Software Mix Are Strategic Moats: Proprietary, regulated AI and a rising software share create long-term competitive differentiation, but require continued investment and customer education.
- Watch for Pipeline Conversion and Margin Trajectory: Investors should focus on the pace of pipeline-to-revenue conversion and the realization of cost savings as primary indicators for second-half and 2027 setup.
Conclusion
Certara’s Q2 2026 marks a critical inflection in its evolution toward a software-first, AI-enabled platform model. With foundational resets largely complete, the company’s next phase will be defined by operational execution and the ability to unlock growth from a robust pipeline.
Industry Read-Through
Certara’s pivot toward software and regulated AI is emblematic of a broader trend in life sciences toward digital, model-informed drug development. The company’s ability to embed AI in both product and operational workflows sets a new standard for productivity and regulatory alignment, raising the bar for peers. The global regulatory harmonization (ICH M15, FDA guidance) and rapid adoption of cloud-based biosimulation tools suggest that vendors who can offer validated, scalable, and auditable AI solutions will capture share. Life sciences and CROs should expect increased competitive intensity and a shift in customer expectations toward integrated, AI-powered platforms. Certara’s experience also highlights the importance of cost discipline and commercial model agility as the industry navigates post-pandemic normalization and evolving regulatory landscapes.